View clinical trials related to Ocular Hypertension.
Filter by:This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any possible long-term adverse consequences of increased iris pigmentation and to follow serious adverse events throughout the study period.
Compare the antihypertensive efficacy of three methods for installing Xalatan
This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment. Eligible patients may be enrolled at the baseline visit. All current ocular hypotensive therapy must be discontinued at this time. On baseline day, patients eligible for the study will receive Xalacom which is to be instilled in the morning.
The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week treatment.
The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
To determine the safety and IOP-lowering ability of a test compound in patients with open-angle glaucoma or ocular hypertension.